Published in J Natl Compr Canc Netw on November 01, 2010
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA (2013) 5.71
Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol (2014) 4.75
Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer (2013) 4.46
BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol (2014) 3.68
Use of radioactive iodine for thyroid cancer. JAMA (2011) 2.98
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid (2013) 1.45
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid (2015) 1.42
Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease. J Thyroid Res (2012) 1.19
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
Variation in the management of thyroid cancer. J Clin Endocrinol Metab (2013) 1.15
Robotic thyroidectomy by bilateral axillo-breast approach: review of 1,026 cases and surgical completeness. Surg Endosc (2013) 1.14
Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab (2015) 1.08
Radioiodine for remnant ablation and therapy of metastatic disease. Nat Rev Endocrinol (2011) 1.07
The Treatment of Well-Differentiated Thyroid Carcinoma. Dtsch Arztebl Int (2015) 1.06
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol (2012) 1.00
Papillary Thyroid Carcinoma Treated with Radiofrequency Ablation in a Patient with Hypertrophic Cardiomyopathy: A Case Report. Korean J Radiol (2016) 0.95
Obesity and risk of thyroid cancer: evidence from a meta-analysis of 21 observational studies. Med Sci Monit (2015) 0.92
Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab (2015) 0.92
Genetics and epigenetics of sporadic thyroid cancer. Mol Cell Endocrinol (2013) 0.85
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist (2014) 0.84
Association of ATM Gene Polymorphism with PTC Metastasis in Female Patients. Int J Endocrinol (2014) 0.83
Thyroid cancer in 2010: a roadmap for targeted therapies. Nat Rev Endocrinol (2011) 0.81
Pediatric thyroid disease: when is surgery necessary, and who should be operating on our children? J Clin Res Pediatr Endocrinol (2012) 0.81
Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1 cm. J Thyroid Res (2013) 0.80
Hyperfunction thyroid nodules: their risk for becoming or being associated with thyroid cancers. Korean J Radiol (2013) 0.79
The prognostic implication and potential role of BRAF mutation in the decision to perform elective neck dissection for thyroid cancer. Gland Surg (2013) 0.78
Use of the afirma® gene expression classifier for preoperative identification of benign thyroid nodules with indeterminate fine needle aspiration cytopathology. PLoS Curr (2013) 0.78
Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors. PLoS One (2016) 0.78
Curcumin inhibits hypoxia-induced migration in K1 papillary thyroid cancer cells. Exp Biol Med (Maywood) (2014) 0.77
Thyroid Disease and Surgery in CHEER: The Nation's Otolaryngology-Head and Neck Surgery Practice-Based Network. Otolaryngol Head Neck Surg (2016) 0.77
An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type. Oncotarget (2016) 0.77
Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Diagn Pathol (2016) 0.77
ProNGF is a potential diagnostic biomarker for thyroid cancer. Oncotarget (2016) 0.76
Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules. Oncol Lett (2015) 0.76
Evaluation and management of the pediatric thyroid nodule. Oncologist (2014) 0.76
Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. Oncotarget (2016) 0.75
Molecular profiling of thyroid nodule fine-needle aspiration cytology. Nat Rev Endocrinol (2017) 0.75
A new strategy for the surgical management of RLN infiltrated by well-differentiated thyroid carcinoma. Biomed Res Int (2014) 0.75
Influence of body habitus on the surgical outcomes of bilateral axillo-breast approach robotic thyroidectomy in papillary thyroid carcinoma patients. Ann Surg Treat Res (2016) 0.75
Downregulation of LSD1 suppresses the proliferation, tumorigenicity and invasion of papillary thyroid carcinoma K1 cells. Oncol Lett (2016) 0.75
Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer. Mol Imaging Radionucl Ther (2016) 0.75
Correlation Between Surgical Extent and Prognosis in Node-Negative, Early-Stage Papillary Thyroid Carcinoma Originating in the Isthmus. World J Surg (2016) 0.75
Is There Justification for Total Thyroidectomy in Low-Risk Papillary Thyroid Carcinoma? A Decision-Analysis Model. World J Surg (2015) 0.75
Controversies in the Management of Low-Risk Differentiated Thyroid Cancer. Endocr Rev (2017) 0.75
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med (2003) 13.99
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst (2008) 12.77
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2005) 8.60
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06
Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol (2002) 6.92
TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med (2007) 5.92
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med (2015) 5.57
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med (2015) 5.07
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology (2005) 4.96
Extent of surgery affects survival for papillary thyroid cancer. Ann Surg (2007) 4.73
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med (2010) 4.00
Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol (2011) 3.95
Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients. Cancer Prev Res (Phila) (2009) 3.70
Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. Cancer (2008) 3.68
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol (2013) 3.37
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol (2011) 3.31
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol (2009) 3.23
Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care (2012) 3.20
Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol (2012) 3.18
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood (2009) 2.91
The so-called stunning of thyroid tissue. J Nucl Med (2006) 2.86
Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg (2003) 2.80
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab (2010) 2.74
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.72
Surgery for asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab (2009) 2.71
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck (2009) 2.59
High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg (2003) 2.56
Psychological, behavioral, and immune changes after a psychological intervention: a clinical trial. J Clin Oncol (2004) 2.55
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol (2008) 2.55
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45
A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid (2008) 2.41
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys (2011) 2.36
The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg (2007) 2.36
Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab (2007) 2.29
Parathyroid cyst: often mistaken for a thyroid cyst. World J Surg (2007) 2.26
NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw (2009) 2.25
Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood (2008) 2.24
In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood (2008) 2.23
Notch inhibits Ptf1 function and acinar cell differentiation in developing mouse and zebrafish pancreas. Development (2004) 2.21
Management of recurrent inguinal hernias. J Am Coll Surg (2009) 2.21
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract (2009) 2.14
Evidence-based surgical management of substernal goiter. World J Surg (2008) 2.12
The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery (2008) 2.11
Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer (2008) 2.09
Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med (2014) 2.09
Prospective functional voice assessment in patients undergoing thyroid surgery. Ann Surg (2002) 2.08
Human papillomavirus-associated adenocarcinoma of the base of the tongue. Hum Pathol (2013) 2.08
ACR Appropriateness Criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil. Head Neck (2012) 2.07
Primary mucosal malignant melanoma of the head and neck. Head Neck (2002) 2.07
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol (2002) 2.07
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
The NIH criteria for parathyroidectomy in asymptomatic primary hyperparathyroidism: are they too limited? Ann Surg (2004) 2.05
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS). Thyroid (2014) 2.04
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol (2007) 2.03
TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin (2005) 2.03
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res (2009) 2.01
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol (2006) 1.97
Insulin gene expression is regulated by DNA methylation. PLoS One (2009) 1.97
Craniofacial surgery for malignant skull base tumors: report of an international collaborative study. Cancer (2003) 1.94
One hundred two patients with pheochromocytoma treated at a single institution since the introduction of laparoscopic adrenalectomy. Arch Surg (2010) 1.94
Neuroendocrine tumors. J Natl Compr Canc Netw (2012) 1.91
Laparoscopic skills are improved with LapMentor training: results of a randomized, double-blinded study. Ann Surg (2006) 1.91
Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care (2010) 1.91
Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab (2002) 1.91